HIV PEP Drugs: Viread® (tenofovir) nucleotide analogue reverse transcriptase inhibitor (NRTI)

Tenofovir (Viread®) was invented by Antonín Holý from at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic and patented in 1984, making this one of the earliest antiviral drugs. In collaboration with Gilead Sciences and the University of California, it was developed into its current form and was approved for… Continue reading

HIV prevention: The Emerging Prevention Regimen from Post-exposure to Pre-exposure Prophylaxis

Like vaccinations for life-threatening diseases such as Hepatitis B and Tetanus, the HIV virus could be tackled more efficiently with the presence of a vaccination for this disease. Researchers have been successful in developing a pre-exposure prophylaxis (PrEP) for HIV which is now a leading development towards finally creating a vaccine. Pre-exposure prophylaxis is a… Continue reading

New York State Department of Health AIDS Institute recently updated their HIV PEP guidelines

The New York State Department of Health AIDS Institute (NYSDHAI) recently tasked their Medical Care Criteria Committee (MCCC) to update their HIV PEP (Post-exposure Prophylaxis) guidelines. PEP refers to the treatment required and administered after exposure to HIV – a sexually transmitted disease (STD). This exposure is categorised as resulting from sexual assault, occupational exposure,… Continue reading